<em>Targeted Therapies in Oncology</em>, an oncology resource that provides oncology professionals with cutting-edge research, data, and treatment strategies surrounding molecular and immune system targets, welcomes Arjun V. Balar, MD, as its editor-in-chief.
Arjun V. Balar, MD
Arjun V. Balar, MD
Targeted Therapies in Oncology, an oncology resource that provides oncology professionals with cutting-edge research, data, and treatment strategies surrounding molecular and immune system targets, welcomes Arjun V. Balar, MD, as its editor-in-chief.
In this role, Balar will work closely with the editorial team to promote major targeted therapy innovations. He will also be responsible for sharing novel studies on the spectrum of cancer research and targeted therapies.
“We are thrilled to have Dr Balar join our team,” said Michael J. Hennessy Jr, president of MJH Associates Inc., parent company of Targeted Oncology. “His expertise from the field of oncology will help our team continue to deliver unprecedented information and data to the community.” Balar added, “I am excited to begin this new role, leading this informative publication in providing the most current, timely and practice-changing research and oncology news coverage to the community.”
Balar is an assistant professor in the department of medicine and serves as the director of the genitourinary medical oncology program at NYU Langone’s Perlmutter Cancer Center. He primarily focuses on treating and managing genitourinary cancers, such as prostate cancer, bladder cancer, kidney cancer and testicular cancer. His research concentration includes immunotherapy and molecularly-targeted therapy.
For more information on Targeted Therapies in Oncology, visit www.targetedonc.com.
About Targeted Oncology
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More
Nivolumab With Gemcitabine-Cisplatin Boosts Survival in Metastatic Urothelial Carcinoma
May 5th 2024Combination therapy with nivolumab and gemcitabine-cisplatin showed promising results in treating metastatic urothelial carcinoma with significantly improved overall survival and progression-free survival rates.
Read More